AX-2025-019224
Enclomiphene citrate · 12.5 mg declared · SinoPep Biotechnology (Changzhou) Co., Ltd. · lot SNP-2503-J5227
- Report ID
- AX-2025-019224
- Compound
- Enclomiphene citrate
- Compound class
- Non-peptide adjuncts
- Supplier
- SinoPep — SinoPep Biotechnology (Changzhou) Co., Ltd.
- Batch / lot
- SNP-2503-J5227
- Declared label claim
- 13mg
- Laboratory
- VendorInvestigate
- Assay date
- 24 Jul 2025
- Submitted
- 29 Jul 2025
- Quarter
- 2025-Q3
- Submitter
- f.duarte
- Sample provenance
- Buyer-sourced
Results
Measured against the index acceptance specification for the non-peptide adjuncts class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.
| Parameter | Method | Result | Unit | Index spec | |
|---|---|---|---|---|---|
| Purity | RP-HPLC, 32 min gradient, 214 nm | 98.14 | % area | ≥ 98.5 | FAIL |
| Total impurities | RP-HPLC, sum of reported peaks | 1.86 | % area | ≤ 1.5 | FAIL |
| Largest single impurity | RP-HPLC — zuclomiphene (cis-isomer) | 0.96 | % area | ≤ 1.00 | PASS |
| Identity — theoretical monoisotopic mass | calculated from molecular formula | 597.2130 | Da | — | NOT TESTED |
| Identity — observed monoisotopic mass | LC-MS, high resolution (ESI-TOF/QTOF) | 597.2150 | Da | — | NOT TESTED |
| Mass accuracy | observed vs theoretical | +3.3 | ppm | ± 10 | PASS |
| Total peptide content | by difference from the gravimetric mass balance | 66.34 | %w/w | — | NOT TESTED |
| Target-compound content | total peptide content × purity | 65.11 | %w/w | — | NOT TESTED |
| Gross fill (as weighed) | five-place balance, under nitrogen | 18.20 | mg | 12.5 mg declared | NOT TESTED |
| Recovered target peptide | gross fill × target content | 11.850 | mg | 12.5 mg claim | NOT TESTED |
| Recovery against label claim | recovered ÷ claim | 94.8 | % | 90.0 – 110.0 | PASS |
| Water content | Karl Fischer, coulometric, duplicate | 4.31 | % | ≤ 10.0 | PASS |
| Counter-ion (citrate) | anion-exchange ion chromatography | 28.76 | % | ≤ 12.0 | FAIL |
| Residual solvent + inorganic residue | estimated — see /methods/residual-solvents-q3c/ | 0.59 | % | — | NOT TESTED |
| Endotoxin | not ordered on this submission | not determined | — | ≤ 5.0 | NOT TESTED |
| Sterility | not ordered on this submission | not determined | — | no growth | NOT TESTED |
| Appearance | visual, diffuse light, black and white background | Off-white lyophilised cake, intact | — | white to off-white intact cake | PASS |
| Reconstitution clarity | reconstituted per submitter procedure | Clear with a single visible fibre | — | clear, no visible particulates | FAIL |
| pH (reconstituted, 1 mg/mL) | potentiometric, two-point calibration | 4.60 | — | 2.5 – 8.0 | PASS |
| Retention time (observed) | RP-HPLC, 32 min gradient | 17.51 | min | 17.45 ± 0.35 (normalised) | PASS |
| Peak asymmetry (10 % height) | Ph. Eur. 2.2.46 | 0.98 | — | 0.80 – 1.50 | PASS |
| Plate count, main peak | N = 5.54 (t/w½)² | 82,121 | — | ≥ 20,000 | PASS |
| Resolution to nearest impurity | vs free base (des-citrate) | 0.09 | — | no index criterion | REPORTED |
Chromatogram and peak integration
The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.
| # | Peak | RT | Area (µV·s) | % area | Δ mass (Da) |
|---|---|---|---|---|---|
| 1 | Enclomiphene citrate — main peak | 17.51 | 4,769,908 | 98.14 | — |
| 2 | zuclomiphene (cis-isomer) | 16.85 | 46,659 | 0.96 | 0.000 |
| 3 | des-ethyl enclomiphene (−28 Da) | 17.04 | 20,899 | 0.43 | -28.031 |
| 4 | N-oxide (+16 Da) | 16.57 | 11,665 | 0.24 | +15.995 |
| 5 | free base (des-citrate) | 17.53 | 11,179 | 0.23 | -192.027 |
| Closure check — purity + Σ impurities | 100.00 | CLOSES | |||
Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.
Mass spectrum and identity
Theoretical monoisotopic mass 597.2130 Da, computed from C26H28ClNO · C6H8O7. All ppm figures on this site are against monoisotopic values — see why that matters.
| Charge | Theoretical m/z | Observed m/z | Δ m/z | Rel. abundance (%) |
|---|---|---|---|---|
| 1+ | 598.2203 | 598.2223 | 0.0020 | 100.0 |
Gravimetric mass balance
Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.
| Component | Determination | %w/w of cake |
|---|---|---|
| Water | Karl Fischer | 4.31 |
| Counter-ion (citrate) | ion chromatography | 28.76 |
| Residual solvent + inorganic residue | estimated | 0.59 |
| Total peptide content | by difference | 66.34 |
| Total | 100.00 CLOSES | |
Supplier certificate, as declared
The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.
| Figure | Supplier COA | This report | Index note |
|---|---|---|---|
| Purity (% area) | 98.89 | 98.14 | divergence +0.07 pp vs batch median |
| Total impurities (% area) | not stated | 1.86 | |
| Largest single impurity (% area) | not stated | 0.96 | |
| Water (%) | 3.9 | 4.31 | |
| Counter-ion (%) | not stated | 28.76 | |
| Peptide content (%w/w) | not stated | 66.34 | |
| Endotoxin (EU/mg) | not stated | not determined | |
| Method stated on certificate | YES | — | column, gradient and wavelength given |
Provenance and caveats
Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.
- Sample provenance
- Buyer-sourced
- Evidentiary weight
- Strongest available evidence in this index.
- Chain of custody
- Retail purchase → submitter (ambient, 23 d) → laboratory (courier, cold pack, 10 d) → assay.
- Assay date
- 24 Jul 2025
- Submitted to the index
- 29 Jul 2025
- Laboratory
- VendorInvestigate, Riga, Latvia
- Method basis
- 32 min gradient · high-resolution MS
- Verification status
- PARTIAL
Annotations 3
Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.
Related records
Same batch — lot SNP-2503-J5227 n=4
| Report | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|
| AX-2025-019223 | SNP-2503-J5227 | Nordanalyt | 2025-Q3 | 99.01 | 4.06 | — | Buyer-sourced | 1 | FAIL |
| AX-2025-019225 | SNP-2503-J5227 | Janoshik | 2025-Q3 | 99.03 | 4.96 | — | Laboratory-retained | 0 | FAIL |
| AX-2025-019226 | SNP-2503-J5227 | Medutest | 2025-Q3 | 98.63 | 4.69 | 91.6 | Buyer-sourced | 1 | FAIL |
Cross-sections
| Report | Supplier | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-041525 | QSC | QSC-2604-R6644 | PeptideMeter | 2026-Q2 | 99.80 | 4.04 | 101.5 | Laboratory-retained | 0 | FAIL |
| AX-2026-042329 | TFC | TFC-2605-H2745 | Nordanalyt | 2026-Q2 | 99.41 | 3.67 | — | Buyer-sourced | 2 | FAIL |
| AX-2026-041524 | QSC | QSC-2604-R6644 | PeptideMeter | 2026-Q2 | 99.93 | 4.60 | 91.6 | Buyer-sourced | 0 | FAIL |
| AX-2026-041526 | QSC | QSC-2604-R6644 | Medutest | 2026-Q2 | 99.68 | 4.25 | 103.7 | Buyer-sourced | 1 | FAIL |
| AX-2026-043164 | SSA | SSA-2603-C7061 | Kestrel | 2026-Q2 | 98.48 | 3.27 | 107.4 | Buyer-sourced | 2 | FAIL |
| AX-2026-041773 | ASY | ASY-{CAT}-1806 | Janoshik | 2025-Q4 | 99.88 | 3.59 | — | Buyer-sourced | 1 | FAIL |
| AX-2025-019360 | HYB | HYB-2510-J6404 | Medutest | 2025-Q4 | 99.61 | 5.07 | 98.1 | Laboratory-retained | 0 | FAIL |
| AX-2025-018986 | ASY | ASY-{CAT}-1806 | Medutest | 2025-Q4 | 99.93 | 3.35 | — | Buyer-sourced | 1 | FAIL |
| Report | Compound | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-041867 | CJC-1295 with DAC | SNP-2607-C3886 | Janoshik | 2026-Q3 | 99.24 | 5.12 | — | Laboratory-retained | 1 | FAIL |
| AX-2026-041913 | Ipamorelin | SNP-2606-L4478 | PeptideMeter | 2026-Q3 | 98.88 | 5.28 | — | Buyer-sourced | 0 | FAIL |
| AX-2026-041914 | Ipamorelin | SNP-2606-L4478 | Janoshik | 2026-Q3 | 99.14 | 5.49 | — | Buyer-sourced | 0 | PASS |
| AX-2026-041909 | Ipamorelin | SNP-2606-L4478 | PeptideMeter | 2026-Q3 | 99.00 | 5.48 | 89.5 | Buyer-sourced | 1 | MARGINAL |
| AX-2026-041895 | Ipamorelin | SNP-2602-B3833 | Janoshik | 2026-Q3 | 99.93 | 4.72 | 105.9 | Buyer-sourced | 1 | MARGINAL |
| AX-2026-041930 | IGF-1 LR3 | SNP-2606-D4620 | Medutest | 2026-Q3 | 98.54 | 5.37 | 93.8 | Buyer-sourced | 0 | PASS |
| AX-2026-041898 | Ipamorelin | SNP-2602-B3833 | Nordanalyt | 2026-Q3 | 99.93 | 4.54 | 96.0 | Buyer-sourced | 1 | MARGINAL |
| AX-2026-041931 | IGF-1 LR3 | SNP-2606-D4620 | PeptideMeter | 2026-Q3 | 97.93 | 5.19 | 93.4 | Buyer-sourced | 0 | PASS |